AIM:To investigate the effect of acetyl-L-carnitine(ALCAR)on cell viability,morphological integrity,and vascular endothelial growth factor(VEGF)expression in human retinal pigment epithelium(ARPE-19)cells using a hypo...AIM:To investigate the effect of acetyl-L-carnitine(ALCAR)on cell viability,morphological integrity,and vascular endothelial growth factor(VEGF)expression in human retinal pigment epithelium(ARPE-19)cells using a hypoxic model.METHODS:In the first set of experiments,the optimal CoCl_(2) dose was determined by exposing ARPE-19 cell cultures to different concentrations.To evaluate the effect of ALCAR on cell viability,five groups of ARPE-19 cell culture were established that included a control group,a sham group(200μM CoCl_(2)),and groups that received 1,10 and 100 mM doses of ALCAR combined with 200μM CoCl_(2),respectively.The cell viability was measured by MTT assay.The morphological characteristics of cells were observed by an inverted phase contrast microscope.The levels of VEGF and HIF-1α secretion by ARPE-19 cells were detected by enzyme linked immunosorbent assay(ELISA)assay.RESULTS:ARPE-19 cells were exposed to different doses of CoCl_(2) in order to create a hypoxia model.Nevertheless,when exposed to a concentration of 200μM CoCl_(2),a notable decrease in viability to 83% was noted.ALCAR was found to increase the cell viability at 1 mM and 10 mM concentrations,while the highest concentration(100 mM)did not have an added effect.The cell viability was found to be significantly higher in the groups treated with a concentration of 1 mM and 10 mM ALCAR compared to the Sham group(P=0.041,P=0.019,respectively).The cell viability and morphology remained unaffected by the greatest dose of ALCAR(100 mM).The administration of 10 mM ALCAR demonstrated a statistically significant reduction in the levels of VEGF and HIF-1α compared with the Sham group(P=0.013,P=0.033,respectively).CONCLUSION:The findings from the current study indicate that ALCAR could represent a viable therapeutic option with the potential to open up novel treatment pathways for retinal diseases,particular relevance for age-related macular degeneration(AMD).However,to fully elucidate ALCAR’s application potential in retinal diseases,additional 展开更多
目的探讨输注聚合人脐带血血红蛋白氧载体(PolyCHb)增强肝癌荷瘤裸鼠对仑伐替尼治疗敏感性的作用机制。方法建立Hep3B肝癌细胞系裸鼠皮下移植瘤模型,将18只荷瘤小鼠随机均分为对照组:生理盐水灌胃90 mg·kg -1·d^(-1);单药组:...目的探讨输注聚合人脐带血血红蛋白氧载体(PolyCHb)增强肝癌荷瘤裸鼠对仑伐替尼治疗敏感性的作用机制。方法建立Hep3B肝癌细胞系裸鼠皮下移植瘤模型,将18只荷瘤小鼠随机均分为对照组:生理盐水灌胃90 mg·kg -1·d^(-1);单药组:仑伐替尼灌胃10 mg·kg^(-1)·d^(-1);增敏组:仑伐替尼灌胃10 mg·kg^(-1)·d^(-1),PolyCHb尾静脉注射600 mg·kg^(-1),2次/周;3组均连续给药28 d,定时测量肿瘤体积、绘制肿瘤生长曲线,在29 d处死裸鼠,剥瘤称取肿瘤重量并做苏木精-伊红染色法(HE)切片评价各组肿瘤的病理形态学;免疫组化(IHC)法测定各组肿瘤组织中缺氧诱导因子(HIF-1α)、CD34、血管内皮生长因子(VEGF)、CD44、基质金属蛋白酶9(MMP-9)、葡萄糖转运蛋白1 (GLUT-1)的表达量;二氢乙锭法测定各组肿瘤组织中活性氧(ROS)的含量。结果 29 d(给药28 d结束后24 h),对照组、单药组及增敏组分别为肝癌荷瘤裸鼠肿瘤体积(mm3):2 076.46±350.25 vs 1 035.96±84.16 vs 892.66±104.46(P<0.05);肿瘤重量(g):1.61±0.52 vs 0.45±0.10 vs 0.34±0.13(P<0.05);IHC评分(分):HIF-1α分别为75±23 vs 45±18 vs 18±11,VEGF分别为52±8 vs 67±16 vs 35±4,CD34分别为40±7 vs 50±13 vs 28±7,CD44分别为37±15 vs 30±7 vs 15±3,GLUT-1分别为74±41 vs 51±30 vs 14±18,MMP-9分别为51±7 vs 62±20 vs 33±3(均为P<0.05);HE切片染色评价:增敏组的肿瘤恶性程度明显低于单药组和对照组;肿瘤组织的ROS含量评价:增敏组较单药组、对照组有所提高。结论 PolyCHb的氧合作用,降低了裸鼠肝癌移植瘤模型中HIF-1α及其下游通路相关分子的表达,在一定时间内延缓了肿瘤生长,提升增强了仑伐替尼的疗效。展开更多
文摘AIM:To investigate the effect of acetyl-L-carnitine(ALCAR)on cell viability,morphological integrity,and vascular endothelial growth factor(VEGF)expression in human retinal pigment epithelium(ARPE-19)cells using a hypoxic model.METHODS:In the first set of experiments,the optimal CoCl_(2) dose was determined by exposing ARPE-19 cell cultures to different concentrations.To evaluate the effect of ALCAR on cell viability,five groups of ARPE-19 cell culture were established that included a control group,a sham group(200μM CoCl_(2)),and groups that received 1,10 and 100 mM doses of ALCAR combined with 200μM CoCl_(2),respectively.The cell viability was measured by MTT assay.The morphological characteristics of cells were observed by an inverted phase contrast microscope.The levels of VEGF and HIF-1α secretion by ARPE-19 cells were detected by enzyme linked immunosorbent assay(ELISA)assay.RESULTS:ARPE-19 cells were exposed to different doses of CoCl_(2) in order to create a hypoxia model.Nevertheless,when exposed to a concentration of 200μM CoCl_(2),a notable decrease in viability to 83% was noted.ALCAR was found to increase the cell viability at 1 mM and 10 mM concentrations,while the highest concentration(100 mM)did not have an added effect.The cell viability was found to be significantly higher in the groups treated with a concentration of 1 mM and 10 mM ALCAR compared to the Sham group(P=0.041,P=0.019,respectively).The cell viability and morphology remained unaffected by the greatest dose of ALCAR(100 mM).The administration of 10 mM ALCAR demonstrated a statistically significant reduction in the levels of VEGF and HIF-1α compared with the Sham group(P=0.013,P=0.033,respectively).CONCLUSION:The findings from the current study indicate that ALCAR could represent a viable therapeutic option with the potential to open up novel treatment pathways for retinal diseases,particular relevance for age-related macular degeneration(AMD).However,to fully elucidate ALCAR’s application potential in retinal diseases,additional
文摘目的探讨输注聚合人脐带血血红蛋白氧载体(PolyCHb)增强肝癌荷瘤裸鼠对仑伐替尼治疗敏感性的作用机制。方法建立Hep3B肝癌细胞系裸鼠皮下移植瘤模型,将18只荷瘤小鼠随机均分为对照组:生理盐水灌胃90 mg·kg -1·d^(-1);单药组:仑伐替尼灌胃10 mg·kg^(-1)·d^(-1);增敏组:仑伐替尼灌胃10 mg·kg^(-1)·d^(-1),PolyCHb尾静脉注射600 mg·kg^(-1),2次/周;3组均连续给药28 d,定时测量肿瘤体积、绘制肿瘤生长曲线,在29 d处死裸鼠,剥瘤称取肿瘤重量并做苏木精-伊红染色法(HE)切片评价各组肿瘤的病理形态学;免疫组化(IHC)法测定各组肿瘤组织中缺氧诱导因子(HIF-1α)、CD34、血管内皮生长因子(VEGF)、CD44、基质金属蛋白酶9(MMP-9)、葡萄糖转运蛋白1 (GLUT-1)的表达量;二氢乙锭法测定各组肿瘤组织中活性氧(ROS)的含量。结果 29 d(给药28 d结束后24 h),对照组、单药组及增敏组分别为肝癌荷瘤裸鼠肿瘤体积(mm3):2 076.46±350.25 vs 1 035.96±84.16 vs 892.66±104.46(P<0.05);肿瘤重量(g):1.61±0.52 vs 0.45±0.10 vs 0.34±0.13(P<0.05);IHC评分(分):HIF-1α分别为75±23 vs 45±18 vs 18±11,VEGF分别为52±8 vs 67±16 vs 35±4,CD34分别为40±7 vs 50±13 vs 28±7,CD44分别为37±15 vs 30±7 vs 15±3,GLUT-1分别为74±41 vs 51±30 vs 14±18,MMP-9分别为51±7 vs 62±20 vs 33±3(均为P<0.05);HE切片染色评价:增敏组的肿瘤恶性程度明显低于单药组和对照组;肿瘤组织的ROS含量评价:增敏组较单药组、对照组有所提高。结论 PolyCHb的氧合作用,降低了裸鼠肝癌移植瘤模型中HIF-1α及其下游通路相关分子的表达,在一定时间内延缓了肿瘤生长,提升增强了仑伐替尼的疗效。
